The gulf journal of oncology最新文献

{"title":"Case Report | FH-Deficient Uterine Leiomyomas: Pathological Insights into a Rare Tumor.","authors":"Varun Goel, Arpit Jain, Dharmistha Basu, Nivedita Patnaik, Vineet Talwar, Siddhant Swamy, Sudhir Rawal","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-based chemotherapy is the standard first-line treatment for advanced urothelial carcinoma of the bladder. Many patients cannot receive cisplatin due to advanced age, renal insufficiency, and poor performance status. As an alternative, gemcitabine-carboplatin (GCa) is frequently used, yet the comparative efficacy of GCa vs. gemcitabine-cisplatin (GC) in real-world settings remains uncertain.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 100 patients with advanced urothelial carcinoma who received either GC (n=60) or GCa (n=40) from January 2022 to December 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), and side effects of therapy. Kaplan-Meier methods were used to calculate survival curves.</p><p><strong>Results: </strong>The median PFS was 7.6 months (GC) vs 5.4 months (GCa) (p=0.03). The median OS was 13.8 months (GC) vs 10.1 months (GCa) (p=0.04). The ORR was higher in the GC group (GC, 42% versus GCa, 30%), but not statistically significant (p=0.08). Renal toxicity (grade 3/4) was higher in the GC group (18% vs 6%, p=0.02).</p><p><strong>Conclusion: </strong>GC demonstrates improved efficacy compared to GCa in terms of PFS and OS, although this comes with renal toxicity. GCa can be a reasonable option for patients not receiving cisplatin.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"67-71"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes and prognostic factors of extragonadal germ cell tumors: An institutional experience over a decade.","authors":"S Bindhu, Meher Lakshmi Konatam, Rachana Chennamaneni, Sadashivudu Gundeti","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Extra gonadal germ cell tumors (EGCT) are rare tumors with late presentation to the oncologist. Though they respond well to chemotherapy, cure is compromised in the real world due to various factors. This study was undertaken to assess the clinical profile, survival outcomes and factors effecting outcomes of extragonadal germ cell tumors in men.</p><p><strong>Patients and methods: </strong>This is a retrospective study of male extra gonadal germ cell tumors diagnosed and treated from January 2011 to December 2021. Patient demographics, tumor characteristics and treatment details were retrieved from case records.</p><p><strong>Statistical analysis: </strong>Kaplan-Meier estimates of survival was used for survival analysis. Cox regression model was used to analyze the prognostic factors using SPSS version 25.</p><p><strong>Results: </strong>A total of 32 patients were analyzed. The median age at presentation was 26 years (range:13-40years). Primary site of the disease was mediastinal in 25patients (78%), retroperitoneal in 4(12%) and intracranial in 3patients (10%). Histology was non seminomatous in majority of mediastinal tumors (15 patients (60%)) while all the retroperitoneal tumors were non seminomatous. Ninety four percent of the patients completed the planned cycles of chemotherapy. BEP was the most common chemotherapy regimen used (n-21 ,65%). Post chemotherapy residual disease was present in 13 patients (10 nonseminomatous, 3 seminomatous), who underwent surgery (9 patients) and radiotherapy (3patients). Median time to relapse was 8 months (range 1-11). Univariate analysis showed that nonseminoma histology, mediastinal site, post chemotherapy elevated tumor markers, Eastern Cooperative Oncology Group performance status (ECOG PS) more than 2, poor risk on International Germ Cell Cancer Collaborative Group (IGCCCG) risk stratification were associated with inferior outcomes. On multivariate analysis, non-seminoma histology, mediastinal site, ECOG PS >2 and IGCCCG poor risk were associated with statistically inferior OS. At a median follow up of 65 months (range 1-132 months) 2-year PFS and OS were both 100% in seminoma and both 65% in non-seminoma.</p><p><strong>Conclusions: </strong>Mediastinum is the most common site of EGCT. Site of the primary, non-seminoma histology, poor performance status and poor risk disease are factors contributing to inferior outcome and high mortality. Early medical attention and newer salvage therapies for refractory disease are needed to improve the survival of these patients.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"7-14"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns and Trends of Colorectal Cancer in the United Arab Emirates: A Retrospective Cohort Study, 2012-2021.","authors":"Ahmad Amrou, Ali Al-Najjar, Rachid Kaddoura, Masa Alashkar, Zainab Al-Abdullah, Samuel B Ho, Neshteman Oghanna, Faisel Ikram, Shroque Zaher","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the third most diagnosed cancer and the second most fatal cancer worldwide. Recent data indicate that colorectal cancer incidence may be increasing in younger age groups. Our primary objective was to assess patterns and trends of colorectal cancer in a tertiary care hospital in Dubai.</p><p><strong>Methods: </strong>Retrospective cohort study, where data from 560 patients diagnosed with CRC in a tertiary care hospital in Dubai, United Arab Emirates (UAE) from 2012 up to 2021 were analyzed. Studied data included sociodemographic, clinical, and histopathologic variables.</p><p><strong>Results: </strong>The incidence rate of CRC cases increased from 29.9 cases per 1000 patients in 2012 to 118 cases per 1000 patients in 2020, followed by a decrease in 2021 following the COVID-19 pandemic. The frequency of CRC was higher among males (56.4%) compared to females (43.4%). The mean age of patients was 54.8 years old (SD = 13.7). Prevalent nationalities included Emirati (21.6%), Indian (10.4%), and United Kingdom (UK) (8.8%). 175/406 (43.1%) had locally advanced disease (pT4) and 134/424 (31.6%) had metastatic disease at presentation. The percentage of CRC cases diagnosed at ages less than 50 years was consistently high over time, ranging from 24-50% of total CRC cases.</p><p><strong>Discussion and conclusion: </strong>The results indicate an alarming increase in the incidence of CRC, including within the younger population aged ≤50 years. CRC incidence increased from 2012 through 2021 in this tertiary center in Dubai and was common in younger age groups, with the majority diagnosed in advanced stages. This indicates the need for increased screening in this region.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"23-30"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytotoxic Effect of Chemotherapy in Women with Breast Cancer in the Wilaya of Oran.","authors":"Zainab Al Lawati, Alaa Al Lawati","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Over the past fifty years, the field of cancer research has witnessed enormous growth and a wealth of knowledge gain, as it remains to be among the primary causes of death across the globe. As a result, significant advancement in cancer therapy has been achieved, particularly in the ones that target specific hallmarks in the process of tumor formation. These hallmarks are renowned as functional competences that enable malignant cells to subsist, grow and spread within the human body. Twenty-one years ago, six main traits were identified, to which two additions were made eleven years later. These are identified as self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, deregulating cellular energetics and avoiding immune destruction. Two supporting characteristics believed to empower the attainment of these hallmarks were also tagged, being instability and mutation of the gene and inflammation fostered by the malignant growth. This paper will highlight the main processes underpinning the self-sufficiency in growth signalling component. It will briefly discuss the process behind cell signaling and mechanisms by which tumors evade the immune system. Following that, it will delve into the therapeutic modality targeting this component and give some current illustrations of how therapies targeting this hallmark are being utilized. Keywords: Cancer hallmarks, cell signaling, sustained proliferative signaling, EGFR antagonists.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"31-36"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Radiotherapy for Early-Stage Laryngeal Cancer: A 12-Year Retrospective Review.","authors":"K Shehzad, N Alrajhi, M Alwhaid, A Alnagmy, M Shehadeh, A Alsemali, M Gamal, M Aldehaim","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Simple Summary: This single-institution retrospective study from King Faisal Specialist Hospital and Research Center in Riyadh examined radiotherapy outcomes in 62 patients with early-stage laryngeal cancer (Tis, T1-T2 N0M0) treated between 2009-2021. The investigation compared three fractionation schedules: 60 Gy/25 fractions, 63 Gy/28 fractions, and 66 Gy/33 fractions, with hypofractionated regimens predominating (&gt;90% of patients). Tomotherapy emerged as the preferred treatment technique (66.1% of cases). At 5-year follow-up, the study demonstrated promising outcomes with overall survival of 80.2%, local control of 80.5%, regional control of 96.77%, and cancer-specific survival of 84.6%. Despite the cohort's high smoking prevalence, these results align with international reports, supporting external beam radiotherapy as an effective and safe approach for early-stage laryngeal malignancies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Laryngeal cancer commonly originates in the glottic region and frequently presents at early stage (cT1-T2 N0M0, AJCC 8th edition). Both external beam radiation therapy (EBRT) and surgery demonstrate excellent efficacy as single-modality treatments for these early-stage malignancies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a retrospective analysis of patients with early laryngeal carcinoma (Tis, T1-T2 N0M0) treated exclusively with External beam radiation therapy EBRT at King Faisal Specialist Hospital and Research Center in Riyadh from 2009-2021. Treatment consisted of one of three fractionation schedules (60Gy/25, 63Gy/28, or 66Gy/33) delivered via Tomotherapy, 3DCRT, or IMRT/VMAT. We evaluated demographic characteristics, risk factors, and multiple survival endpoints including local control, regional control, overall survival, and cancer-specific survival.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The study comprised 62 patients (mean age: 60.4 years), predominantly male (90.3%) with high smoking prevalence (74.2%). All patients presented with voice hoarseness. Hypofractionated regimens were administered to over 90% of patients, with Tomotherapy being the most utilized technique (66.1%), followed by IMRT/VMAT (25.8%) and 3DCRT (8.1%). Treatment was well-tolerated with no grade 3-4 toxicities and manageable early side effects. The 5-year outcomes demonstrated favorable results: local control (80.5%), regional control (96.77%), overall survival (80.2%), and cancer-specific survival (84.6%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Definitive radiotherapy has demonstrated efficacy and safety as a primary treatment modality for early-stage laryngeal cancer, consistent with prior studies. The outcomes from our cohort, despite the notably high prevalence of smokers, are comparable to international benchmarks, further confirming external beam radiotherapy's role as an effective therapeutic option for early-stage laryngeal carcinoma. Nonetheless, the significant smoking rates observed in our patient population highlight the critical n","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"37-47"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review.","authors":"Varun Goel, Arpit Jain, Dharmistha Basu, Nivedita Patnaik, Vineet Talwar, Siddhant Swamy, Sudhir Rawal","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-based chemotherapy is the standard first-line treatment for advanced urothelial carcinoma of the bladder. Many patients cannot receive cisplatin due to advanced age, renal insufficiency, and poor performance status. As an alternative, gemcitabine-carboplatin (GCa) is frequently used, yet the comparative efficacy of GCa vs. gemcitabine-cisplatin (GC) in real-world settings remains uncertain.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 100 patients with advanced urothelial carcinoma who received either GC (n=60) or GCa (n=40) from January 2022 to December 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), and side effects of therapy. Kaplan-Meier methods were used to calculate survival curves.</p><p><strong>Results: </strong>The median PFS was 7.6 months (GC) vs 5.4 months (GCa) (p=0.03). The median OS was 13.8 months (GC) vs 10.1 months (GCa) (p=0.04). The ORR was higher in the GC group (GC, 42% versus GCa, 30%), but not statistically significant (p=0.08). Renal toxicity (grade 3/4) was higher in the GC group (18% vs 6%, p=0.02).</p><p><strong>Conclusion: </strong>GC demonstrates improved efficacy compared to GCa in terms of PFS and OS, although this comes with renal toxicity. GCa can be a reasonable option for patients not receiving cisplatin.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"60-66"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baroreflex Sensitivity, Vascular Status, and Cardiorespiratory Fitness In Breast Cancer Survivors - A Cross-sectional Analytical Study.","authors":"Aashish S Raman, Rajalakshmi Rajasegaran, Govindarajan Vishnukanth, Rajeswari Aghoram, Biswajit Dubashi, Usha Dhanaradja, Allen Timothy","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most prevalent malignancy, affecting millions annually. Although advancements in therapeutic measures have resulted in diminished mortality rates, the cardiovascular and pulmonary side effects of these therapies raise clinical concerns.</p><p><strong>Methods: </strong>This cross-sectional study evaluated baroreflex sensitivity (BRS), vascular status, pulmonary function and cardiorespiratory fitness (CRF) in 33 breast cancer survivors (BCS) aged 30-60 years, two to three years post-treatment, compared to 33 age and BMI-matched healthy females.</p><p><strong>Results: </strong>BRS was significantly lower in BCS (p<0.05), indicating autonomic dysfunction. Pulmonary function tests revealed reduced FEV1, FVC, FEV1/FVC ratio, FEF25%-75%, and PEFR in BCS (p<0.05), suggesting impaired respiratory health. CRF was also diminished, with a significantly lower VO2 max in BCS compared to controls (31.2 ± 13.1 ml/kg/min vs. 37.4 ± 11 ml/kg/min, p=0.041). Furthermore, the Ruffier Dickson Index (RDI) was significantly higher in BCS than in controls (5.8 ± 2.2 vs. 4.6 ± 1.3, P=0.009), indicating reduced cardiovascular fitness and recovery efficiency after physical exertion. However, no significant differences were observed in carotid intima-media thickness (CIMT) or blood pressure parameters between the groups. A statistically significant association was found in RDI categories between groups (χ² = 6.554, P=0.038), indicating a difference in RDI grading distribution between healthy controls and breast cancer survivors.</p><p><strong>Conclusion: </strong>Breast cancer survivors are at increased risk of impaired cardiac autonomic and pulmonary functions, likely as a result of the adverse effects of chemotherapy and radiotherapy. These findings highlight the need for comprehensive post-treatment monitoring and targeted rehabilitation strategies to mitigate cardiopulmonary risks and enhance the quality of life of these individuals.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"15-22"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of specific human papilloma virus DNA PCR to detect HPV in oral squamous cell carcinoma.","authors":"Preeti R Doshi, Rachana Lakhe, Annu Christopher, Avantika Jain, Reena P Bharadwaj","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Head and neck cancers represent the sixth most common cancer worldwide with approximately 630,000 new patients diagnosed annually resulting in more than 350,000 deaths every year. It is essential for the understanding the biological behavior of oral squamous cell carcinomas and pre-cancerous lesions that may be responsible for malignant transformation. Heterogeneity in prevalence and anatomic distribution are associated to demographic differences in the habits of exposure to tobacco and alcohol. It has been demonstrated that HPV infection is an independent prognostic factor, even in smoking patients, with 58% reduction of the risk of death. The wide variation in HPV prevalence can be attributed to different detection techniques, small sample numbers, differences in the lesions and sampling techniques and epidemiological characteristics of the populations studied. Among the many methods to detect HPV infections, polymerase chain reaction (PCR) have been well validated. HPV-positive oral squamous cell carcinomas may have a better prognosis than HPV-negative oral squamous cell carcinomas as HPV specific therapies may be available in near future. This study has been an effort to find out the incidence of HPV in oral squamous cell carcinoma in our setting.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"48-52"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Spectrum of Sarcoma in the Sultanate of Oman.","authors":"Maitha Al Sibani, Ajit Venniyoor, Kawther Al Lawati, Ahmed AlLawati, Maryam Al Nabhani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcomas are a group of malignant tumors arising from mesenchymal tissue, with variable presentations and outcomes. Multiple factors contribute to the prognosis of the disease. As they are relatively infrequent, data on their clinical spectra and treatment outcomes are limited. The aim of this study is to identify the clinical spectrum of sarcomas in the Sultanate of Oman.</p><p><strong>Methods: </strong>This is a single-center, retrospective study, conducted in The Royal Hospital, Muscat. The target population was sarcoma patients aged 18 years and above, who were diagnosed and treated over 5 years between 2016 to 2020 in this hospital.</p><p><strong>Results: </strong>A total of 234 patients with histologically proven soft tissue and bone sarcomas were included in the study. The median age of the patients was 43 years. Soft tissue sarcomas (STS) constituted the most common type (72.2%). The most common histopathologic subtype of STS was uterine sarcoma at 25.8%, followed by gastrointestinal stromal tumors (GIST) (12.4%). Among 234 patients, 60 patients had metastatic disease and received palliative chemotherapy, and 174 patients were treated with curative intent. The mean progression free survival (PFS) in localized and metastatic bone sarcomas was 52.0 months and 10 months respectively. In STS cohort, the mean PFS in localized and metastatic was 33.0 months and 23.0 respectively. The mean of overall survival (OS) was 58.8 months and 11.8 months in localized and metastatic bone sarcomas while in STS, the mean of OS was 91.0 months and 26.0 months respectively. There was a statistically significant association between age and survival in STS, while the same was not seen in bone sarcomas.</p><p><strong>Conclusion: </strong>Sarcomas are infrequent tumors with variety of histological subtypes and prognosis. We observed a gradual decline in survival with advancing age in the STS group.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"53-59"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report | Primary Squamous Cell Carcinoma of the Thyroid: A Rare Subtype of Anaplastic Carcinoma.","authors":"Fatima Safini, Achraf Miry, Zainab Oumouloud, Ghizlane Ennibi, Sanae Abbaoui, Bouchra Amaoui","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Primary squamous cell carcinoma of the thyroid is an uncommon neoplasm, recently redefined as a variant of anaplastic thyroid carcinoma (ATC). It has a dismal prognosis, with most patients succumbing to the disease within the first year following diagnosis. Due to its rarity, there are no well-established treatment guidelines.</p><p><strong>Case presentation: </strong>In this study, we report a new case of primary squamous cell carcinoma of the thyroid. The patient underwent total thyroidectomy with recurrent lymph node dissection with rapid local recurrence in less than 6 months without adjuvant therapy.</p><p><strong>Discussion and conclusion: </strong>This case highlights the aggressivity of this tumor and emphasizing the necessity of advancements in scientific research, particularly in genomics, with the aim of enhancing survival outcomes for patients with this rare malignancy.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"72-75"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147286151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}